Send to

Choose Destination
J Pharmacol Toxicol Methods. 2018 May - Jun;91:36-42. doi: 10.1016/j.vascn.2018.01.003. Epub 2018 Feb 4.

Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report.

Author information

Pluriomics BV, Galileiweg 8, 2333 BD Leiden, The Netherlands.
Pluriomics BV, Galileiweg 8, 2333 BD Leiden, The Netherlands. Electronic address:
Nanion Technologies GmbH, Ganghoferstraße 70a, D-80339 Munich, Germany.
NMI Natural and Medical Sciences Institute, Markwiesenstraße 55, 72770 Reutlingen, Germany.
Physiostim, Z.I. de Brénas, 81440, Lautrec, France.
Investigative Toxicology, Non-Clinical Development, UCB-Biopharma, Chemin du Foriest, 1420 Braine l'Alleud, Belgium.


Safety pharmacology studies that evaluate drug candidates for potential cardiovascular liabilities remain a critical component of drug development. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have recently emerged as a new and promising tool for preclinical hazard identification and risk assessment of drugs. Recently, Pluriomics organized its first User Meeting entitled 'Combining Pluricyte® Cardiomyocytes & MEA for Safety Pharmacology applications', consisting of scientific sessions and live demonstrations, which provided the opportunity to discuss the application of hiPSC-CMs (Pluricyte® Cardiomyocytes) in cardiac safety assessment to support early decision making in safety pharmacology. This report summarizes the outline and outcome of this Pluriomics User Meeting, which took place on November 24-25, 2016 in Leiden (The Netherlands). To reflect the content of the communications presented at this meeting we have cited key scientific articles and reviews.


Cardiotoxicity; Human-induced pluripotent stem cell-derived cardiomyocytes; Multi-electrode array technology; Safety pharmacology

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center